A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors

This study is testing a new drug called BL-M24D1 in people with advanced non-small cell lung cancer (NSCLC) or other solid tumors that have stopped responding to standard treatments. Researchers are testing safety at different doses and looking for early signs of effectiveness. **You may be eligible if...** - You are 18 years or older (up to 75 for Phase Ia) - You have locally advanced or metastatic NSCLC or another solid tumor - You have at least one measurable tumor - Standard treatments have failed or you cannot tolerate them - Your heart, kidneys, liver, and blood counts are in acceptable range - Your general health allows you to carry out normal activities (ECOG score 0 or 1) **You may NOT be eligible if...** - You have active, uncontrolled brain tumors - You have severe heart problems (ejection fraction below 50%) - You are pregnant or breastfeeding - You have had major surgery or severe infections recently - You are on certain other medications that may interact with the study drug Talk to your doctor to see if this trial is right for you.